Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
447 stopped studies mapped to Primary Malignant Liver Neoplasm and descendants · 93% state a reason
Over the 447 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or… | N/A | terminated | Aug 29, 2016 | University of Washington | Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.) | Enrollment / accrual |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | Phase 2 / Phase 3 | suspended | Sep 2, 2021 | Mirror Biologics, Inc. | Sponsor unable to fund | Funding |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | TriSalus Life Sciences, Inc. | The decision was made to terminate the study after the completion of Phase 1b enrollment and not… | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | Phase 2 | terminated | Aug 8, 2019 | NYU Langone Health | Study was terminated early by the drug sponsor due to slow accrual and a change in the company's… | Enrollment / accrual |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable…(RHEPaiR) | N/A | terminated | Mar 8, 2024 | Imperial College London | Terumo Europe NV permanently discontinued production of Holmium platform SIRT product range | Other (stated, no rule matched) |
| NCT05582018 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA) | N/A | terminated | Oct 17, 2022 | Techsomed Medical Technologies LTD | Sponsor decision | Sponsor / business decision |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H… | Phase 2 | withdrawn | Nov 15, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | Phase 1 | terminated | Aug 6, 2020 | Eureka Therapeutics Inc. | The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to… | Other (stated, no rule matched) |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | Phase 2 | terminated | Aug 18, 2021 | National Cancer Institute (NCI) | Reason for termination was a combination of slow accrual in setting of austerity measures regarding… | Enrollment / accrual |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular…(HOMIE-166) | N/A | terminated | Jul 11, 2022 | Terumo Europe N.V. | The HOMIE-166 clinical investigation was prematurely terminated due to sponsor's decision to… | Sponsor / business decision |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib… | Phase 1 | terminated | Aug 4, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Phase 2 | terminated | Oct 20, 2017 | University Health Network, Toronto | The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further… | Enrollment / accrual |
| NCT07043348 | Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma(ISTAR-04) | — | terminated | Jun 29, 2025 | Seoul National University Hospital | This study was merged with NCT07043387. Thus, this study was terminated. | Other (stated, no rule matched) |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | — | terminated | Sep 23, 2020 | University of Washington | Study terminated due to end of funding | Funding |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04520906 | To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With… | N/A | terminated | Aug 20, 2020 | Suzhou Hengruihongyuan Medical Technology Co. LTD | Obtaining medical device market approval through the predicate device comparison route. | Other (stated, no rule matched) |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic… | Early Phase 1 | withdrawn | Aug 27, 2024 | Shanghai Changzheng Hospital | Based on the results of another intravenous injection therapy CD-801 for the treatment of… | Other (stated, no rule matched) |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma… | Phase 2 | terminated | Apr 17, 2024 | Shandong Cancer Hospital and Institute | Study was terminated due to unacceptable treatment-related toxicity that raised safety concerns and… | Safety / toxicity |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable… | Phase 1 / Phase 2 | terminated | Nov 30, 2022 | Nerviano Medical Sciences | In the Phase II part of the study, among the participants evaluable for efficacy, no objective… | Efficacy / futility |
| NCT05342350 | International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy(STOP-HCC) | — | terminated | Apr 22, 2022 | Johns Hopkins University | PI moving on from current institution | Other (stated, no rule matched) |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | suspended | Nov 2, 2022 | Primocure Pharma | Enrollment paused | Enrollment / accrual |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | Phase 2 | withdrawn | Apr 12, 2024 | Shanghai Zhongshan Hospital | The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted… | Other (stated, no rule matched) |
| NCT03534141 | Mild Hypothermia and Acute Kidney Injury in Liver Transplantation(MHALT) | N/A | terminated | May 23, 2018 | University of California, San Francisco | Terminated 9/24/23 at 85% target enrollment due to slow accrual of subjects. The decline in… | Enrollment / accrual |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line…(SIRCCA) | Phase 2 / Phase 3 | terminated | Jun 21, 2016 | Sirtex Medical | Slow enrollment | Enrollment / accrual |
| NCT04732286 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With… | Phase 3 | terminated | Feb 1, 2021 | Hoffmann-La Roche | The study was completed as pre-specified in the protocol. Study was terminated only for… | Other (stated, no rule matched) |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients… | Phase 1 | terminated | Mar 7, 2023 | Coherus Oncology, Inc. | The study was terminated for strategic reasons (not for safety concerns) | Safety / toxicity |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular… | Phase 2 | withdrawn | Oct 20, 2016 | Medical University of South Carolina | study is being rewritten for different disease population | Other (stated, no rule matched) |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First…(ABE-LIVER) | Phase 2 | terminated | Jul 7, 2022 | University Hospital, Grenoble | Study terminated due to recruitement issues | Enrollment / accrual |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | Phase 2 | terminated | Oct 4, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | slow recruitment | Enrollment / accrual |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of… | N/A | withdrawn | Aug 17, 2018 | Fifth Affiliated Hospital, Sun Yat-Sen University | No participents enrolled | Enrollment / accrual |
| NCT03889093 | Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The… | N/A | terminated | Mar 26, 2019 | University of Minnesota | PI Left Institution | Investigator |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jul 26, 2021 | Tarus Therapeutics, Inc. | Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6).… | Other (stated, no rule matched) |
| NCT06144827 | A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | N/A | withdrawn | Nov 22, 2023 | Montefiore Medical Center | PI indicated that the site was unable to procure shunt. No participants were enrolled and this… | Enrollment / accrual |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT05137899 | Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy(ADVANCE HCC) | Phase 2 | terminated | Nov 30, 2021 | Ontario Clinical Oncology Group (OCOG) | Recruitment challenges, Hoffman La Roche strategic priority shift | Enrollment / accrual |
| NCT05770882 | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | terminated | Mar 16, 2023 | Great Novel Therapeutics Biotech & Medicals Corporation | The overall profile does not support development for Hepatocellular Carcinoma | Other (stated, no rule matched) |
| NCT03812289 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | N/A | terminated | Jan 23, 2019 | OHSU Knight Cancer Institute | PI decision | Other (stated, no rule matched) |
| NCT06848556 | Evaluate the Effect of Tirazamine on Primary Liver Cancer. | Phase 1 / Phase 2 | terminated | Feb 27, 2025 | Zhejiang Raygene Pharmaceuticals Co., Ltd | Company Operational Strategy Adjustment | Sponsor / business decision |
| NCT04268888 | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC(TACE-3) | Phase 2 / Phase 3 | suspended | Feb 13, 2020 | The Clatterbridge Cancer Centre NHS Foundation Trust | Analysis meant the study should close to recruitment | Enrollment / accrual |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced… | Phase 3 | terminated | Jan 14, 2021 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | IDMC recommended to terminate the study since Interim analysis showed that the experimental group… | Efficacy / futility |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | Phase 2 | terminated | Sep 21, 2010 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver… | N/A | suspended | Oct 17, 2016 | St. Louis University | IRB reviewing study conduct and adverse events | Safety / toxicity |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and…(MYCHELANGELO I) | Phase 1 / Phase 2 | terminated | Aug 11, 2022 | Omega Therapeutics | Sponsor decision to terminate after monotherapy dose escalation. | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 17, 2025source: clinicaltrials